Heart failure & cardiomyopathiesSecondary analysis
Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM
- Post-hoc analysis of the ATTRibute-CM randomised trial
- phase 3
Authors' conclusion
Acoramidis led to CMI from baseline in NT-proBNP concentration or 6MWD in a considerable proportion of participants with ATTR-CM.
Study context
- Population
- Participants with ATTR-CM in the phase 3 ATTRibute-CM trialanalysed
- Participants
- 611 participants
- Comparison
- Acoramidis vs placebo
- Acoramidisn = 409
- Placebon = 202reference
- Primary endpoint
- Clinically meaningful improvement (CMI) in NT-proBNP (decrease >700 ng/L and >30%) or 6MWD (increase >35 m)
- Follow-up
- Month 30
Primary result
CMI in NT-proBNP or 6MWD
Odds ratio
3.0
95% CI 1.8–5.1
P < 0.001
By group
Acoramidis vs Placebo
OR 3.0 (95% CI 1.8–5.1); P < 0.001
As reported in the abstract
Original publication
Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM. Eur J Heart Fail. Published 20 February 2026. doi:10.1093/ejhf/xuag048
Summarised from the published abstract; every number is checked against it